Katherine A. High
Katherine A. High | |
|---|---|
High in 2026 | |
| Born | |
| Education | Harvard College, University of North Carolina School of Medicine |
| Known for | Gene Therapy |
| Children | three, including Sarah Steele |
| Scientific career | |
| Fields | Hematology |
| Workplaces | University of Pennsylvania, Spark Therapeutics |
Academic advisors | Edward J. Benz Jr. |
Katherine A. High is an American physician-scientist who is an emeritus professor at the Perelman School of Medicine at the University of Pennsylvania. She was the co-founder, president, and chief scientific officer of Spark Therapeutics and is CEO of the ophthalmology gene therapy company RhyGaze. She has been recognized for her contributions to the field of gene therapy, having designed, sponsored, and conducted the first clinical trial of an adeno-associated viral vector (AAV) gene therapy injected into the skeletal muscle (1999), the first trial of AAV gene therapy introduced into the liver (2001), and the first trial in the US of an AAV gene therapy injected into the subretinal space (2007). She was among the first to elucidate human immune responses to systemically administered AAV vectors, and developed solutions that are used in clinical gene therapy. High is an elected member of the National Academy of Medicine, the National Academy of Sciences, the American Academy of Arts and Sciences, and the Royal College of Physicians.